Chronic myeloid leukemia as an immunological target

American Journal of Hematology

Volumn 54, Issue 1, 1997, Pages 61-67

  Lim, Seah H ^a   Coleman, Sharon ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Chronic myeloid leukemia; Immunotherapy; T cell response

Indexed keywords

CYTOKINE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LEUKEMIA, MYELOID, CHRONIC; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES;

EID: 0031031721     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199701)54:1<61::AID-AJH9>3.0.CO;2-2     Document Type: Article

References (49)

1. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomised study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994.
2. Appelbaum FR: The influence of total dose, fractionation, dose rate, and distribution of total body irradiation on bone marrow transplantation. Semin Oncol [Suppl] 20:3, 1993.
3. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Anti-leukemia effect of graft-versus-host disease in recipients of allogeneic marrow grafts. N Engl J Med 300:1069, 1979.
4. Kolb HJ, Mitteruller J, Clemms C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990.
5. Hale G, Waldmann H: Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplant for malignant diseases. Bone Marrow Transplant 13:597, 1994.
6. Jiang YZ, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ: T cell and NK cell mediated graft-versus-leukaemic reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chonic myeloid leukaemia. Bone Marrow Transplant 11:133, 1993.
7. MacKinnon S, Hows JM, Goldman JM: Induction of graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 76:2037, 1990.
8. Scheffold C, Brandt K, Johnston V, Lefterova P, Degen B, Schontube M, Huhn D, Neubauer A, Schmidt-Wolf IGH: Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 15:33, 1995.
9. Silla LMR, Pincus SM, Locker JD, Glover J, Elder E, Donnenberg AD, Nardi NB, Bryant J, Ball ED, Whiteside TL: Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets. Br J Haematol 93:375, 1996.
10. Lim SH, Newland AC, Kelsey S, Bell A, Offerman E, Rist C, Gozzard D, Bareford D, Smith MP, Goldstone AH: Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia - A phase II study. Cancer Immunol Immunother 34:337, 1992.
11. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F: Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84:2158, 1994.
12. Hamon MD, Prentice HG, Gottlieb DJ, Macdonald ID, Cunningham JM, Smith OP, Gilmore M, Gandhi L, Collis C: Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 11:399, 1993.
13. Sykes M, Pearson DA, Szot GL: IL-2-induced GVHD protection is not inhibited by cyclosporine and is maximal when IL-2 is given over a 25 hour period beginning on the day following bone marrow transplantation. Bone Marrow Transplant 15:395, 1995.
14. Azuma E, Kaplan J: Role of lymphokine-activated killer cells as mediators of veto and natural suppression. J Immunol 141:2601, 1988.
15. Przepiorka D, Ippoliti C, Koberda J, Chan K-W, Khouri IF, Fischer HE, Huh YO, Escudier SM, Seong D, Davis M, Gajewski J, Vriesendorp HM, Champlin RE: Interleukin-2 for prevention of graft-versus-host disease after haploidentical marrow transplantation. Transplantation 58:858, 1994.
16. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964, 1994.
17. Robinson N, Sanders JE, Benyunes MC, Beach K, Lindgren C, Thompson JA, Appelbaum R, Fefer A: Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 87:1249, 1996.
18. Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, Territo M, Ho W, Feig S, Selch M, Isacescu V, Reichert TA, Champlin RE: Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: A randomised controlled trial. Transplantation 57:82, 1994.
19. Somasundaram R, Advani SH, Gangal SG: Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T-cells. Cancer Immunol Immunother 27:183, 1988.
20. Coleman S, Fisher J, Hoy T, Burnett AK, Lim SH: Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia. Leukemia 10:483, 1996.
21. Jiang YZ, Kanfer EJ, Macdonald D, Cullis JO, Goldman JM, Barrett AJ: Graft-versus-leukaemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 8:253, 1991.
22. Datta AR, Barrett AJ, Jiang YZ, Guimaraes A, Mavroudis DA, van Rhee F, Gordon AA, Madrigal A: Distinct T cell populations distinguish chonic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions. Bone Marrow Transplant 14:517, 1994.
23. Falkenberg JHF, Goselink HM, van der Harst D, van Luxemburg-Heijs SAP, Kooy-Winkelaar YMC, Faber LM, de Kroon J, Brand A, Fibbe WE, Willemze R, Goulmy E: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 174:27, 1991.
24. Pardoll DM: Tumour antigens: A new look for the 1990s. Nature 369:357, 1994.
25. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognised by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109, 1995.
26. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA: Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 156:3151, 1996.
27. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M, Bellet O, Guillet J, Paillerets BB: Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 25:1765, 1995.
28. Jung S, Schluesener H: Human T lymphocytes recognise a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173:273, 1991.
29. BCR-ABL protein. Proc Natl Acad Sci USA 89:1468, 1992.
30. BCR-ABL protein by human T cells Leukemia 9:1344, 1995.
31. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: Specific human cellular immunity to BCR-ABL oneogene-derived peptides. Blood 87:3587, 1996.
32. Cullis JO, Barrett AJ, Goldman JM, Lechler RI: Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: Studies in antigen-processing defective cell lines. Leukemia 8:165, 1994.
33. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A: Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 86:2680, 1995.
34. Dermime S, Molldrem J, Parker KC, Jiang YZ, Mavroudis D, Hensel N, Couriel D, Mahoney M, Coligan JE, Barrett AJ: Human CD8+ T lymphocytes recognize the fusion region of BCR-ABL hybrid protein present in chronic myelogenous leukemia. Blood [Suppl] 86:158, 1995.
35. Greco G, Fruci D, Accupezzato D, Barnaba V, Nisini R, Alimena G, Montefusco E, Vigneti R, Tanigaki N, Tosi R: Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 10:693, 1996.
36. Langlade-Demoyen P, Abastado JP, Even J, Gourru G, Leblond V, Binet JL, Kourilsky P: Cytotoxic T cell response against 210 kDA chimeric protein coded by the BCR-ABL fusion gene in chronic myeloid leukemia. Blood [Suppl] 86:525, 1995.
37. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar C, Hale G, Waldmann H, Steinberg SM, Slavin S: T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506, 1995.
38. MacKinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilley RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995.
39. Thiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux J-M, Contassot E, Murphy WJ, Lyons R, Chiang Y, Herve P, Longo D, Ruscetti FW: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84:1333, 1994.
40. Soiffer RJ, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Robertson MJ, Spector N, Gonin R, Miller KB, Rudders RA, Freeman A, Blake K, Coral F, Nadler LM, Ritz J: Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 10:1191, 1992.
41. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Guo J, Lee M, Gajewski J, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin RE: CD8+-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Graft vs. leukemia without graft vs. host disease. Blood 86:4337, 1995.
42. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9, 1995.
43. Walters EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity againist cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995.
44. Young JW, Inaba K: Dendritic cells as adjuvant for class I major histocompatibilily complex-restricted antitumor immunity. J Exp Med 183:7, 1996.
45. Lim SH, Thomas DW, Coleman S, Stephens P: T cell receptor Vβ repertoire of tumour-infiltrating lymphocytes in oral squamous cell carcinoma. Cancer Immunol Immunother 42:69, 1996.
46. Caignard A, Dietrich PY, Morand V, Lim A, Pannetier C, Leridant AM, Hercend T, Even J, Kourilsky P, Triebel F: Evidence for T cell clonal expansion in patients with squamous cell carcinomas of the head and neck. Cancer Res 54:1292, 1994.
47. Gaudin C, Dietrich PY, Robache S, Guillard M, Escudier B, Lacombe MJT, Kumar A, Triebel F, Caignard A: In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res 55:685, 1995.
48. Coleman S, Perera P, Fisher J, Hoy T, Burnett AK, Lim SH: Abnormal TCR Vβ repertoire in patients with chronic myeloid leukaemic. Br J Haematol 90:358, 1995.
49. Ferace F, Kremer F, Dietrich PY, Gandin C, Angevin E, Courtier MH, Bayle C, Hercend T, Triebel F: T cell repertoire in patients with B-chronic lymphocytic leukemia: Evidence for in vivo T cell clonal expansion. J Immunol 153:4281, 1994.